Carrier Screening Market is expected to be worth US$ 4,323.84 million | FMI

 The global Carrier Screening Market is expected to record a CAGR of 12.4% between 2023 and 2033, with a size estimated in 2023 at US$ 1,343.40 million. The market's value is expected to rise to US$ 4,323.84 million by 2033.


As a result of increased funding from the public and commercial sectors in response to the rising demand for genetic tests, the market is predicted to expand. The adoption of accessible technologies is recognized as a key component in carrier screening.

To learn more about this report @ https://www.futuremarketinsights.com/reports/carrier-screening-market

The introduction of innovative tests for better diagnosis and treatment is having an increasing impact on the global carrier screening industry. The sector is growing as a result of the increase in genetic defects and chronic diseases.

Dynamics of the Global Carrier Screening Market

Throughout the projected period, market participants are anticipated to increase their mergers, agreements, and acquisitions. For instance, to sell the extended carrier screening (ECS) test in Hong Kong, Counsyl, Inc. expanded its cooperation with Angsana Molecular & Diagnostics Laboratory in July 2017. Furthermore, Myriad Genetics, Inc. purchased Counsyl, Inc. in July 2018. The acquisition is anticipated to improve Myriad Genetics, Inc.'s portfolio of genetic tests.

Several launches and approvals of new carrier screening tests are probably going to fuel market expansion during the anticipated time.

Regional Insights for the Global Carrier Screening Market

Due to product approvals and the introduction of novel carrier screening tests, North America held the leading market share through 2033. For instance, in October 2019, Sema4 announced the availability of the Expanded Carrier Screen, a test that estimates the likelihood that a kid may inherit a genetic condition.

Due to the introduction and acceptance of new screening tests in the region, Europe is also experiencing profitable growth in the carrier screening industry.

For instance, the QIAseq Expanded Carrier Screening Panel was introduced by the German company QIAGEN in June 2019. For molecular diagnostics, QIAGEN delivers sample and assay technology. About the targets and genes responsible for 200 illness indications are disclosed by the QIAseq.

Key Takeaways

  • With a 12.9% CAGR between 2023 and 2033, the expanded carrier screening (ECS) segment is anticipated to be the key revenue-generating market.
  • Through 2033, the DNA sequencing market sector held a 39.9% revenue share, dominating the carrier screening market.
  • With a 47.1% carrier screening market share throughout the projection period, the laboratory segment dominated the global market.
  • With a share of 40.19% through 2033, the North American market is anticipated to hold a leading position in the carrier screening market.

Genetic Screening is a type of genetic testing that is used to identify whether a person is carrying a gene for a genetic disorder. This screening is typically done before or during pregnancy to identify the risk of having a child with a genetic disorder.

Competitive Landscape

There are several significant participants in the fragmented and competitive carrier screening market. A small number of significant businesses control a large portion of the market.

The market's overall competitive rivalry is growing as a result of the existence of significant players including:

  • Myriad Genetics, Inc
  • Cepheid
  • Illumina
  • Thermo Fisher Scientific Inc.
  • F.Hoffmann-La Roche Ltd
  • Laboratory Corporation of America Holdings
  • Otogenetics
  • MedGenome
  • GeneTech
  • Centogene N.V.

Recent Development

Collaboration – To Co-develop

Illumina and Kartos Therapeutics, Inc. announced a collaboration to co-develop a TP53 companion diagnostic (CDx) in April 2021. This CDx is based on the information provided by Illumina's comprehensive genomic profile assay, TruSight Oncology.

Partnership - Utilizing the Skills of Both Parties

Fulgent and Precision Genomics Laboratory (PGL) partnered in January 2019 to offer Columbia patients on-site performed, expanded carrier screening.

Acquisition – For Expansion

Fulgent purchased CSI Laboratories (CSI) in August 2021 to increase its exposure to somatic molecular diagnostics and cancer testing. CSI provides molecular genetics, immunohistochemistry, fluorescence in-situ hybridization (FISH), and cytogenetic studies.

Key Segments  

By Type:

  • Expanded Carrier Screening
  • Targeted Disease Carrier Screening

By Medical Condition:

  • Cystic Fibrosis
  • Tay-Sachs
  • Gaucher Disease
  • Sickle Cell Disease
  • Spinal Muscular Atrophy
  • Other

By Technology:

  • DNA Sequencing
  • Polymerase Chain Reaction
  • Microarrays
  • Other

By End User:

  • Hospitals
  • Laboratories
  • Physician Offices & Clinics
  • Other

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more